Figure 3.

Identification of NSC85561 from the initial compounds. (a) MDCK cells were treated with the initial nine compounds at the concentration of 100 µM and cell viability was measured using the MTS assay. (b) MDCK cells were infected with A/WSN/1933 (H1N1, 100 PFU) were treated with the mixture at the concentration of 25 µM. A virus plaque reduction assay was performed. (c) Representation of the agglutination of NSC85561 and NSC84472 in serial two-fold dilutions started with 100 µM and was performed in three individual experiments.